# Accuray Incorporated (ARAY)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $35M  
**Price:** $0.34 (+3.03%)

> Accuray Incorporated is a radiation oncology company that develops, manufactures, sells, and supports precise radiation therapy and radiosurgery systems. Its primary purpose is to deliver advanced treatments for tumors and cancers throughout the body, including oncology and neuro-radiosurgery applications, with a focus on complex cases while simplifying routine ones. Key products include the CyberKnife platform, a robotic stereotactic radiosurgery and body radiation therapy system that automatically tracks and corrects for tumor and patient movement in real-time for sub-millimeter accuracy without manual intervention, and the TomoTherapy platform featuring the Radixact System for helical delivery of intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company also provides precision treatment planning software, data management solutions, and support services like the Radiotherapy Support Program. Accuray partners with clinicians and administrators worldwide to enhance patient outcomes and speed recovery. Founded in 1990 and headquartered in Madison, Wisconsin, it maintains manufacturing facilities in the United States and China, along with regional offices across North America, Europe, Asia, and beyond, serving leading healthcare centers globally.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $459M | $147M | $8M | -$2M | — |
| 2024 | $447M | $143M | $504,000 | -$16M | — |
| 2023 | $448M | $154M | $2M | -$9M | — |
| 2022 | $430M | $160M | $8M | -$5M | — |
| 2021 | $396M | $160M | $22M | -$6M | — |
| 2020 | $383M | $150M | $13M | $4M | — |
| 2019 | $419M | $163M | $583,000 | -$16M | — |
| 2018 | $405M | $162M | -$4M | -$24M | — |
| 2017 | $383M | $141M | -$10M | -$30M | — |
| 2016 | $399M | $159M | -$5M | -$26M | — |
| 2015 | $380M | $145M | -$19M | -$40M | — |
| 2014 | $369M | $143M | -$18M | -$35M | — |
| 2013 | $316M | $98M | -$81M | — | — |
| 2012 | $409M | $137M | -$56M | — | — |
| 2011 | $222M | $107M | -$28M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $470M | $389M | $81M | $57M | $137M |
| 2024 | $469M | $424M | $45M | $69M | $172M |
| 2023 | $479M | $426M | $54M | $89M | $177M |
| 2022 | $473M | $420M | $53M | $89M | $180M |
| 2021 | $480M | $411M | $69M | $116M | $174M |
| 2020 | $491M | $427M | $64M | $108M | $189M |
| 2019 | $438M | $388M | $50M | $77M | $160M |
| 2018 | $379M | $330M | $49M | $83M | $131M |
| 2017 | $406M | $360M | $47M | $72M | $165M |
| 2016 | $469M | $409M | $60M | $120M | $210M |
| 2015 | $467M | $391M | $76M | $80M | $203M |
| 2014 | $495M | $397M | $99M | $92M | $196M |
| 2013 | $476M | $369M | $107M | $73M | $199M |
| 2012 | $473M | $269M | $204M | $144M | $79M |
| 2011 | $456M | $215M | $240M | $96M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $3M | $4M | -$1M |
| 2024 | -$12M | $4M | -$16M |
| 2023 | $16M | $13M | $3M |
| 2022 | -$2M | $5M | -$7M |
| 2021 | $39M | $2M | $36M |
| 2020 | -$1M | $4M | -$5M |
| 2019 | -$30M | $4M | -$34M |
| 2018 | $18M | $6M | $12M |
| 2017 | -$380,000 | $5M | -$5M |
| 2016 | $31M | $8M | $23M |
| 2015 | -$14M | $10M | -$25M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ARAY)